TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: This 2 arm study will compare the effect of Avastin + irinotecan versus temozolomide, in combination with conventional involved field radiotherapy, in patients with newly diagnosed glioblastoma and a non-methylated MGMT promoter. Patients will be randomized 3:1 to receive Avastin 10mg/kg iv every 2 weeks + irinotecan 125mg/m2 iv every 2 weeks, or temozolomide 75mg/m2 po daily during radiotherapy followed by 6 cycles of temozolomide 150-200mg/m2 po daily on days 1-5 of each 4 week cycle. The anticipated time on study treatment is until disease progression, and the target sample size is 100-500 individuals.


Options:
A: Arm Label: Calibration Arm; Type: EXPERIMENTAL; Interventions: Drug: fotemustine | Arm Label: Investigational Arm; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab [Avastin] | Intervention Type: DRUG; Name: bevacizumab [Avastin]; Assigned to Arm(s): Investigational Arm | Intervention Type: DRUG; Name: fotemustine; Assigned to Arm(s): Calibration Arm
B: Arm Label: Bevacizumab + RT + Temozolomide; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Temozolomide, Radiation: Radiation therapy | Arm Label: Placebo + RT + Temozolomide; Type: PLACEBO_COMPARATOR; Interventions: Drug: Temozolomide, Radiation: Radiation therapy, Drug: Placebo | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Bevacizumab + RT + Temozolomide | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): Bevacizumab + RT + Temozolomide, Placebo + RT + Temozolomide | Intervention Type: RADIATION; Name: Radiation therapy; Assigned to Arm(s): Bevacizumab + RT + Temozolomide, Placebo + RT + Temozolomide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + RT + Temozolomide
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab [Avastin], Drug: irinotecan | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: temozolomide | Intervention Type: DRUG; Name: bevacizumab [Avastin]; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: irinotecan; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: temozolomide; Assigned to Arm(s): 2
D: Arm Label: Cediranib 30mg; Type: EXPERIMENTAL; Interventions: Drug: Cediranib | Arm Label: Cediranib 20mg + lomustine; Type: OTHER; Interventions: Drug: Cediranib, Drug: Lomustine Chemotherapy | Arm Label: Lomustine and Placebo Cediranib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lomustine Chemotherapy, Drug: Placebo Cediranib | Intervention Type: DRUG; Name: Cediranib; Assigned to Arm(s): Cediranib 30mg | Intervention Type: DRUG; Name: Cediranib; Assigned to Arm(s): Cediranib 20mg + lomustine | Intervention Type: DRUG; Name: Lomustine Chemotherapy; Assigned to Arm(s): Cediranib 20mg + lomustine, Lomustine and Placebo Cediranib | Intervention Type: DRUG; Name: Placebo Cediranib; Assigned to Arm(s): Lomustine and Placebo Cediranib

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: This 2 arm study will compare the effect of Avastin + irinotecan versus temozolomide, in combination with conventional involved field radiotherapy, in patients with newly diagnosed glioblastoma and a non-methylated MGMT promoter. Patients will be randomized 3:1 to receive Avastin 10mg/kg iv every 2 weeks + irinotecan 125mg/m2 iv every 2 weeks, or temozolomide 75mg/m2 po daily during radiotherapy followed by 6 cycles of temozolomide 150-200mg/m2 po daily on days 1-5 of each 4 week cycle. The anticipated time on study treatment is until disease progression, and the target sample size is 100-500 individuals.


Options:
A: Arm Label: Arm 1 - Short Course Radiotherapy; Type: EXPERIMENTAL; Interventions: Radiation: Radiotherapy | Arm Label: Arm 2 - Standard Course Radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Radiotherapy | Intervention Type: RADIATION; Name: Radiotherapy; Assigned to Arm(s): Arm 1 - Short Course Radiotherapy | Intervention Type: RADIATION; Name: Radiotherapy; Assigned to Arm(s): Arm 2 - Standard Course Radiotherapy
B: Arm Label: 5-aminolevulinic acid; Type: EXPERIMENTAL; Interventions: Drug: 5-aminolevulinic acid (5-ALA) | Arm Label: Conventional resection; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: 5-aminolevulinic acid (5-ALA); Assigned to Arm(s): 5-aminolevulinic acid
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab [Avastin], Drug: irinotecan | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: temozolomide | Intervention Type: DRUG; Name: bevacizumab [Avastin]; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: irinotecan; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: temozolomide; Assigned to Arm(s): 2
D: Arm Label: Rindopepimut/GM-CSF plus Temozolomide; Type: EXPERIMENTAL; Interventions: Drug: Rindopepimut (CDX-110) with GM-CSF, Drug: Temozolomide | Arm Label: KLH plus Temozolomide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Temozolomide, Drug: KLH | Intervention Type: DRUG; Name: Rindopepimut (CDX-110) with GM-CSF; Assigned to Arm(s): Rindopepimut/GM-CSF plus Temozolomide | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): KLH plus Temozolomide, Rindopepimut/GM-CSF plus Temozolomide | Intervention Type: DRUG; Name: KLH; Assigned to Arm(s): KLH plus Temozolomide

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: TIPPS - Thrombophilia in Pregnancy Prophylaxis Study: A Multicentre, Multinational, Randomized Control Trial of Prophylaxis Low Molecular Weight Heparin (LMWH) in High-risk Thrombophilic Women.
Brief Summary: The TIPPS trial seeks to determine the safety and effectiveness of low-molecular-weight heparin (LMWH), an anticoagulant, in preventing placenta mediated pregnancy complications and venous thromboembolism (VTE) in women with thrombophilia. Thus, the principal research question is: can LMWH prevent thrombosis in the leg veins, pulmonary arteries and placental vessels, thereby reducing the risk of deep vein thrombosis, pulmonary embolism (PE), intrauterine growth restriction (IUGR), preeclampsia, miscarriage and stillbirth?


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: dalteparin sodium; Type: ACTIVE_COMPARATOR; Interventions: Drug: dalteparin sodium | Intervention Type: DRUG; Name: dalteparin sodium; Assigned to Arm(s): dalteparin sodium
B: Intervention Type: DRUG; Name: Low dose steroids; Assigned to Arm(s): N/A
C: Arm Label: Granulocyte colony stimulating factor; Type: EXPERIMENTAL; Interventions: Drug: G-CSF | Arm Label: placebo (saline solution); Type: PLACEBO_COMPARATOR; Interventions: Drug: saline solution | Intervention Type: DRUG; Name: G-CSF; Assigned to Arm(s): Granulocyte colony stimulating factor | Intervention Type: DRUG; Name: saline solution; Assigned to Arm(s): placebo (saline solution)
D: Arm Label: enoxaparin fixed; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: enoxaparin adjusted; Type: EXPERIMENTAL; Interventions: Drug: enoxaparin | Intervention Type: DRUG; Name: enoxaparin; Assigned to Arm(s): enoxaparin adjusted

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: TIPPS - Thrombophilia in Pregnancy Prophylaxis Study: A Multicentre, Multinational, Randomized Control Trial of Prophylaxis Low Molecular Weight Heparin (LMWH) in High-risk Thrombophilic Women.
Brief Summary: The TIPPS trial seeks to determine the safety and effectiveness of low-molecular-weight heparin (LMWH), an anticoagulant, in preventing placenta mediated pregnancy complications and venous thromboembolism (VTE) in women with thrombophilia. Thus, the principal research question is: can LMWH prevent thrombosis in the leg veins, pulmonary arteries and placental vessels, thereby reducing the risk of deep vein thrombosis, pulmonary embolism (PE), intrauterine growth restriction (IUGR), preeclampsia, miscarriage and stillbirth?


Options:
A: Arm Label: Aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: acetylsalicylic-acid (aspirin) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Folic acid | Intervention Type: DRUG; Name: acetylsalicylic-acid (aspirin); Assigned to Arm(s): Aspirin | Intervention Type: DIETARY_SUPPLEMENT; Name: Folic acid; Assigned to Arm(s): Placebo
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: dalteparin sodium; Type: ACTIVE_COMPARATOR; Interventions: Drug: dalteparin sodium | Intervention Type: DRUG; Name: dalteparin sodium; Assigned to Arm(s): dalteparin sodium
C: Arm Label: Standard of Care Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Low-molecular-weight heparin | Arm Label: Experimental Arm; Type: EXPERIMENTAL; Interventions: Drug: Aspirin 81 mg | Intervention Type: DRUG; Name: Aspirin 81 mg; Assigned to Arm(s): Experimental Arm | Intervention Type: DRUG; Name: Low-molecular-weight heparin; Assigned to Arm(s): Standard of Care Arm
D: Arm Label: enoxaparin fixed; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: enoxaparin adjusted; Type: EXPERIMENTAL; Interventions: Drug: enoxaparin | Intervention Type: DRUG; Name: enoxaparin; Assigned to Arm(s): enoxaparin adjusted

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of a Physical-activity-promoting Environment on Motor Skills, Physical Activity, Quality of Life and BMI of Children in Childcare Settings (Youp'là Bouge)
Brief Summary: The purpose of the study is to evaluate the effect of a project promoting unstructured spontaneous physical activity (PA) through an adaptation of the built environment and the provision of a supportive social environment of childcare centers on motor skills, physical activity, desire to move around, body mass index (BMI), quality of life and PA and behavior of the family.


Options:
A: Arm Label: Control group: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle intervention | Intervention Type: BEHAVIORAL; Name: Lifestyle intervention; Assigned to Arm(s): Intervention group
B: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle intervention | Intervention Type: BEHAVIORAL; Name: Lifestyle intervention; Assigned to Arm(s): Intervention group
C: Arm Label: Educational intervention, Control; Type: EXPERIMENTAL; Interventions: Other: Educational program | Arm Label: Educational program; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Educational program; Assigned to Arm(s): Educational intervention, Control
D: Arm Label: Healthy Buddies Curriculum; Type: EXPERIMENTAL; Interventions: Other: Healthy Buddies Curriculum | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Healthy Buddies Curriculum; Assigned to Arm(s): Healthy Buddies Curriculum

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Developing and Testing a Tamoxifen Prophylaxis Decision Aid
Brief Summary: RATIONALE: Evaluating a decision aid that describes the risks and benefits of taking tamoxifen citrate to prevent breast cancer may be helpful for women at increased risk of breast cancer.

PURPOSE: This randomized phase I/II trial is studying tamoxifen citrate decision aids for women at increased risk of breast cancer.


Options:
A: Arm Label: Decision support; Type: EXPERIMENTAL; Interventions: Other: Feeding Options in Dementia Decision Aid | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Feeding Options in Dementia Decision Aid; Assigned to Arm(s): Decision support
B: Arm Label: Decision Aid Tool; Type: EXPERIMENTAL; Interventions: Behavioral: Decision Aid Tool | Arm Label: Control; Type: NO_INTERVENTION; Interventions: Other: Treatment as Usual | Intervention Type: BEHAVIORAL; Name: Decision Aid Tool; Assigned to Arm(s): Decision Aid Tool | Intervention Type: OTHER; Name: Treatment as Usual; Assigned to Arm(s): Control
C: Intervention Type: BEHAVIORAL; Name: Decision Aid; Assigned to Arm(s): N/A
D: Intervention Type: OTHER; Name: informational intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: questionnaire administration; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: survey administration; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Study Comparing Irradiation at a Dose of 80 Gy to Irradiation at 70 Gy in Unfavorable Prostate Cancers Associated With Prolonged Hormonal Therapy
Brief Summary: RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. It is not yet known which dose of radiation therapy is more effective in treating patients with prostate cancer.

PURPOSE: This randomized phase III trial is comparing two radiation therapy regimens in treating patients with prostate cancer receiving hormone therapy.


Options:
A: Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Radiation: 3-dimensional conformal radiation therapy, Radiation: intensity-modulated radiation therapy | Arm Label: Arm II; Type: EXPERIMENTAL; Interventions: Radiation: 3-dimensional conformal radiation therapy, Radiation: intensity-modulated radiation therapy | Intervention Type: RADIATION; Name: 3-dimensional conformal radiation therapy; Assigned to Arm(s): Arm I, Arm II | Intervention Type: RADIATION; Name: intensity-modulated radiation therapy; Assigned to Arm(s): Arm I, Arm II
B: Arm Label: Intensity Modulated Radiotherapy (IMRT); Type: ACTIVE_COMPARATOR; Interventions: Radiation: Conventional Fractionated Intensity Modulated Radiotherapy | Arm Label: Hypofractionated Intensity Modulated Radiotherapy (HIMRT); Type: EXPERIMENTAL; Interventions: Radiation: Hypofractionated Intensity Modulated Radiotherapy | Intervention Type: RADIATION; Name: Conventional Fractionated Intensity Modulated Radiotherapy; Assigned to Arm(s): Intensity Modulated Radiotherapy (IMRT) | Intervention Type: RADIATION; Name: Hypofractionated Intensity Modulated Radiotherapy; Assigned to Arm(s): Hypofractionated Intensity Modulated Radiotherapy (HIMRT)
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Gray | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Radiation: Gray | Intervention Type: RADIATION; Name: Gray; Assigned to Arm(s): 1 | Intervention Type: RADIATION; Name: Gray; Assigned to Arm(s): 2
D: Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Fibrinogen and Bleeding After Cardiac Surgery
Brief Summary: The study hypothesis is that prophylactic fibrinogen infusion reduces postoperative bleeding and transfusion requirements after coronary artery bypass surgery (CABG) in patients with endogenous fibrinogen levels in the lower normal range. 60 patients will be included in a prospective, randomized double-blind placebo-controlled single center study.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Fibrinogen | Arm Label: Study drug; Type: EXPERIMENTAL; Interventions: Drug: Fibrinogen | Intervention Type: DRUG; Name: Fibrinogen; Assigned to Arm(s): Placebo, Study drug
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic acid | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sodium Chloride 0.9% | Intervention Type: DRUG; Name: Tranexamic acid; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Sodium Chloride 0.9%; Assigned to Arm(s): 2
C: Arm Label: Beriplex® P/N; Type: EXPERIMENTAL; Interventions: Biological: Beriplex® P/N (Kcentra) | Arm Label: Fresh frozen plasma; Type: ACTIVE_COMPARATOR; Interventions: Biological: Fresh frozen plasma | Intervention Type: BIOLOGICAL; Name: Beriplex® P/N (Kcentra); Assigned to Arm(s): Beriplex® P/N | Intervention Type: BIOLOGICAL; Name: Fresh frozen plasma; Assigned to Arm(s): Fresh frozen plasma
D: Arm Label: Fibrinogen if FibTEM < 8 mm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Human fibrinogen concentrate | Arm Label: Fibrinogen if FibTEM < 13 mm; Type: EXPERIMENTAL; Interventions: Drug: Human fibrinogen concentrate | Intervention Type: DRUG; Name: Human fibrinogen concentrate; Assigned to Arm(s): Fibrinogen if FibTEM < 13 mm, Fibrinogen if FibTEM < 8 mm

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Tobacco Treatment Strategies for Inpatient Psychiatry
Brief Summary: This study aims to evaluate, in a randomized controlled trial, tobacco treatments of varying intensities for smokers hospitalized on acute psychiatric inpatient units.


Options:
A: Arm Label: IQOS; Type: EXPERIMENTAL; Interventions: Device: IQOS | Arm Label: E-CIG; Type: ACTIVE_COMPARATOR; Interventions: Device: E-CIG | Intervention Type: DEVICE; Name: IQOS; Assigned to Arm(s): IQOS | Intervention Type: DEVICE; Name: E-CIG; Assigned to Arm(s): E-CIG
B: Arm Label: EGO/CE4, 9mg nicotine; Type: OTHER; Interventions: Device: EGO/CE4, 9mg nicotine | Intervention Type: DEVICE; Name: EGO/CE4, 9mg nicotine; Assigned to Arm(s): EGO/CE4, 9mg nicotine
C: Arm Label: Ecig 24 mg nicotine; Type: EXPERIMENTAL; Interventions: Device: Ecig 24 mg nicotine | Arm Label: Ecig 0 mg nicotine; Type: SHAM_COMPARATOR; Interventions: Device: Ecig 0 mg nicotine | Arm Label: Nicotine free inhalator; Type: PLACEBO_COMPARATOR; Interventions: Device: Nicotine free inhalator | Intervention Type: DEVICE; Name: Ecig 24 mg nicotine; Assigned to Arm(s): Ecig 24 mg nicotine | Intervention Type: DEVICE; Name: Ecig 0 mg nicotine; Assigned to Arm(s): Ecig 0 mg nicotine | Intervention Type: DEVICE; Name: Nicotine free inhalator; Assigned to Arm(s): Nicotine free inhalator
D: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care | Arm Label: Brief Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Brief Intervention | Arm Label: Extended Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Extended Treatment | Intervention Type: BEHAVIORAL; Name: Brief Intervention; Assigned to Arm(s): Brief Treatment | Intervention Type: BEHAVIORAL; Name: Extended Treatment; Assigned to Arm(s): Extended Treatment | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Usual Care

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Tobacco Treatment Strategies for Inpatient Psychiatry
Brief Summary: This study aims to evaluate, in a randomized controlled trial, tobacco treatments of varying intensities for smokers hospitalized on acute psychiatric inpatient units.


Options:
A: Arm Label: cigarette substitute; Type: EXPERIMENTAL; Interventions: Other: cigarette substitute | Arm Label: e-cigarette (with 0 mg/ml nicotine); Type: EXPERIMENTAL; Interventions: Other: e-cigarette | Arm Label: e-cigarette (with 8 mg/ml nicotine); Type: EXPERIMENTAL; Interventions: Other: e-cigarette | Arm Label: e-cigarette (with 36 mg/ml nicotine); Type: EXPERIMENTAL; Interventions: Other: e-cigarette | Intervention Type: OTHER; Name: e-cigarette; Assigned to Arm(s): e-cigarette (with 0 mg/ml nicotine), e-cigarette (with 36 mg/ml nicotine), e-cigarette (with 8 mg/ml nicotine) | Intervention Type: OTHER; Name: cigarette substitute; Assigned to Arm(s): cigarette substitute
B: Arm Label: E-Cigarette 7.2 mg nicotine; Type: EXPERIMENTAL; Interventions: Device: E-Cigarette 7.2 mg nicotine | Intervention Type: DEVICE; Name: E-Cigarette 7.2 mg nicotine; Assigned to Arm(s): E-Cigarette 7.2 mg nicotine
C: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care | Arm Label: Brief Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Brief Intervention | Arm Label: Extended Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Extended Treatment | Intervention Type: BEHAVIORAL; Name: Brief Intervention; Assigned to Arm(s): Brief Treatment | Intervention Type: BEHAVIORAL; Name: Extended Treatment; Assigned to Arm(s): Extended Treatment | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Usual Care
D: Arm Label: Arm I (different type of ENDS product at each visit); Type: EXPERIMENTAL; Interventions: Other: Electronic Cigarette, Other: Laboratory Biomarker Analysis, Other: Pharmacological Study, Other: Questionnaire Administration | Arm Label: Arm II (BLU e-cigarette ENDS product with different flavors); Type: EXPERIMENTAL; Interventions: Other: Electronic Cigarette, Other: Laboratory Biomarker Analysis, Other: Pharmacological Study, Other: Questionnaire Administration | Intervention Type: OTHER; Name: Electronic Cigarette; Assigned to Arm(s): Arm I (different type of ENDS product at each visit) | Intervention Type: OTHER; Name: Electronic Cigarette; Assigned to Arm(s): Arm II (BLU e-cigarette ENDS product with different flavors) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (different type of ENDS product at each visit), Arm II (BLU e-cigarette ENDS product with different flavors) | Intervention Type: OTHER; Name: Pharmacological Study; Assigned to Arm(s): Arm I (different type of ENDS product at each visit), Arm II (BLU e-cigarette ENDS product with different flavors) | Intervention Type: OTHER; Name: Questionnaire Administration; Assigned to Arm(s): Arm I (different type of ENDS product at each visit), Arm II (BLU e-cigarette ENDS product with different flavors)

Answer: C